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Ibrutinib blocks Btk-dependent NF-ĸB and NFAT
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Ibrutinib is a small molecule Bruton tyrosine kinase (Btk) inhibitor
approved by the Food and Drug Administration for clinical use in
the treatment of chronic lymphocytic leukemia, Waldenstro¨m
macroglobulinemia, and as a second-line treatment of lymphoma
and chronic graft-versus-host disease.1 An association with
pulmonary aspergillosis was observed shortly after Ibrutinib
was licensed for use.2 A recent phase Ib study of Ibrutinib
treatment of primary central nervous system lymphoma re-
ported a 39% incidence of invasive aspergillosis, in patients
concurrently treated with corticosteroids, in the absence of
neutropenia.3 Studies of Aspergillus fumigatus infection in Btk2/2
mice revealed focal pneumonia and large airway mucous plugs,
mirroring ﬁndings in macrophage-depleted models of pulmonary
aspergillosis.3
We recently described a key role for Btk in macrophage immune
responses during experimental pulmonary aspergillosis.4 Btk
was critical for endosomal signaling responses during murine
macrophage phagocytosis of A fumigatus. Btk activation led to
calcineurin-NFAT signaling, which was crucial for orchestrating
neutrophil recruitment during pulmonary aspergillosis and was
dependent on the endosomal DNA receptor TLR9. These
observations suggest that defects in macrophage Btk signaling
contribute to susceptibility to pulmonary aspergillosis. Here we
show that Ibrutinib is a potent inhibitor of both NFAT and
nuclear factor k-light-chain-enhancer of activated B cells (NF-kB)
responses in humanmacrophages during infection withA fumigatus.
We show that A fumigatus induces human macrophage Btk
phosphorylation, and that Btk depletion impairs NFAT andNF-kB
responses in human macrophages. Our ﬁndings suggest Btk in-
volvement in a TLR9-dependent endosomally driven pathway in
accordance with previous ﬁndings in our murinemodel. In addition,
our results show that Ibrutinib is a strong inhibitor of macrophage
responses to A fumigates, which may increase the susceptibility of
patients on Ibrutinib to invasive aspergillosis.
Peripheral blood samples were collected from unscreened healthy
donors. THP-1–derived macrophages, human monocyte–derived
macrophages (hMDMs), and alveolar macrophages were isolated
and differentiated as previously described.5 The study was ap-
proved by the Biomedical Research Unit (National Research Ethics
Service reference 10/H0504/9[DAJ3]), Royal Brompton, and
Hareﬁeld NHS Trust.
A fumigatus strain CEA10 (FGSC A1163) and Candida albicans
ATCC 90028 were obtained from the Fungal Genetics Stock
Center. ATCC 46645-eGFP was a kind gift from Frank Ebel
(Germany). Strains were cultured as previously described.5
Macrophages were incubated with 1 mM Ibrutinib (Selleck
Chemicals), 10 mm ODN2088 (TLR9-blocking nucleotide), 10 mM
ODN20958 (control nucleotide, Miltenyi Biotec), 50 mg/mL zy-
mosan, or vehicle. SMARTpool siGENOME BTK small interfering
RNA (siRNA; Dharmacon) was used at a concentration of 75 nM.
For siRNA knockdown, primary monocyte cells were differenti-
ated for 7 days. On day 4, siRNA was transfected using VIromer
Blue (Lipocalyx) according to the manufacturer’s instructions.
Scramble siRNA was used as a control for all experiments.
Confocal microscopy was performed as previously described.5
Cells were permeabilized in phosphate-buffered saline con-
taining 10% goat serum and 0.1% Saponin (Sigma, UK) for
2 hours and then incubated overnight at 4°C with a primary
antibody (anti-NFATc1, clone 7A6, BD Biosciences; anti-NF-kB
p65, clone F6, Santa-Cruz Biotech; anti-BTK, clone 7F12H4,
Novus Biologicals) in blocking buffer. After washing with
phosphate-buffered saline, cells were incubated with anti-rabbit
Cy5 or anti-mouse Cy5 antibody (Life Technologies) for 45
minutes at room temperature and mounted with Vectashield
mounting medium containing 49,6-diamidino-2-phenylindole
(DAPI; Vector Laboratories).
Tumor necrosis factor-a (TNF-a) release was quantiﬁed in culture
supernatants using DuoSet ELISA Development kit (R&D Sys-
tems) following the manufacturer’s instructions. Galactomannan
was quantiﬁed in supernatants using Platelia Aspergillus Ag kit
(Bio-Rad) following the manufacturer’s instructions. Western
blotting for nuclear and cytoplasmic fractions was performed as
previously described.5 For Btk phosphorylation studies, mac-
rophages were incubated in 100 mM sodium pervanadate for
2 hours at 4°C prior to cell lysis. Membranes were probed with
anti-NFATc1 (7A6; Santa-Cruz), anti-NFkB p65 (C22B4), anti-
HDAC1 (10E2), anti-histone H3 (D1H2), anti-phospho-BTK (Tyr
223), and anti-BTK (D3H5) antibodies, all from Cell Signaling.
To determine whether A fumigatus activates Btk macrophages,
THP-1 macrophages were infected with swollen conidia and
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phosphorylation of Btk at Tyr 223 determined by western
blotting (Figure 1A). Infection induced phosphorylation of Btk,
which was blocked by Ibrutinib. In addition, Ibrutinib inhibited A
fumigatus–dependent nuclear translocation of NFAT and NF-ĸB
(Figure 1B). Zymosan, but notC albicans, was able to induce BTK
phosphorylation (supplemental Figure 1, available on the Blood
Web site). The role of Btk in NFAT and NF-ĸB translocation was
conﬁrmed by Btk siRNA knockdown duringA fumigatus infection
of hMDMs, by confocal microscopy (Figure 1C-D; supplemental
Figure 2). Accordingly, both Ibrutinib and Btk siRNA inhibited
hMDM and alveolar macrophage TNF-a responses during A
fumigatus infection (Figure 1E-H). These observations indicate
that Ibrutinib blocks inﬂammatory responses to A fumigatus in
human macrophages through a Btk-dependent pathway.
Our murine studies indicated that Btk-dependent macrophage
responses to A fumigatus are mediated through an endosomal
TLR9 signaling pathway.4 Consistent with these observations,
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Figure 1. Ibrutinib blocks Btk-dependent activation of NFAT and NF-kB in human macrophages during A fumigatus infection. (A) A fumigatus induces autophos-
phorylation of Btk at Tyr 223, and this is inhibited by Ibrutinib. THP1 macrophages were pretreated with Ibrutinib (1 mM) for 1 hour. Cells were stimulated with A fumigatus
swollen conidia (multiplicity of infection [MOI]5 5) for up to 2 hours. Whole cell lysates were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE), followed by western blotting. Membranes were probed with anti-pBTK and anti-BTK antibodies. (B) BTK phosphorylation is required for NFAT and NF-kB activation
in response to A fumigatus in THP1 macrophages. THP1 macrophages were pretreated with Ibrutinib (1 mM) for 1 hour. Cells were stimulated with A fumigatus swollen
conidia (MOI5 5) for up to 2 hours. Whole cell lysates were separated by SDS-PAGE, followed by western blotting. Membranes were probed with anti-NFATc1, NF-kB, and
HDAC antibodies. (C-D) BTK mediates NFAT and NF-ĸB activation pathways in hMDMs (supplemental Figure 2). Monocyte-derived macrophages were pretreated with
Scramble or BTK-targeting siRNA (75 nM) for 72 hours. Cells were stimulated with eGFP A fumigatus swollen conidia (MOI 5 1) for 1 hour, and NFATc1 and NF-kB
translocation were measured by confocal microscopy. Nuclear translocation was quantiﬁed by calculating the percent overlap of the nuclear DAPI and transcription factor-
linked ﬂuorophore channels. Data were calculated from 7 ﬁelds of view taken at random per biological repeat. Mean and standard deviation of 3 biological repeats are
represented. Statistical analysis was performed using paired Student t tests: ns, not signiﬁcant; *P , .05; NS, nonstimulated. N 5 3. Af, A fumigatus; Ca, C albicans; Zym,
zymosan. (E-H) TNF-a release by human macrophages in response to A fumigatus is BTK dependent. Monocyte-derived macrophages (E,G-H) and alveolar macrophages
(F) were pretreated with Ibrutinib (1 mM) for 1 hour or scramble or BTK-targeting siRNA (100 nM) for 72 hours. (E-G) Macrophages were stimulated with A fumigatus swollen
conidia (MOI 5 1) for 16 hours. TNF-a levels in the tissue culture supernatants were measured by enzyme-linked immunosorbent assay. (H) Whole cell lysates were
separated by SDS-PAGE, followed by western blotting. Membranes were probed with anti-BTK and anti–b-actin antibodies. Statistical analysis was performed using paired
Student t tests. *P , .05. NS, nonstimulated. N 5 3 to 5.
1986 blood® 1 NOVEMBER 2018 | VOLUME 132, NUMBER 18 LETTERS TO BLOOD
For personal use only.on November 19, 2018. by guest  www.bloodjournal.orgFrom 
A fumigatus–dependent NFAT translocation in hMDMs was
blocked by both Ibrutinib and the TLR9-blocking nucleotide
ODN2088 (Figure 2A). Furthermore, inhibition of phagocytosis
of A fumigatus by hMDMs using cytochalasin D led to a loss of
Btk-dependency for NFAT-dependent signaling responses
(Figure 2B). In accordance with this ﬁnding, cytochalasin
D inhibited Btk phosphorylation in hMDMs during A fumigatus
infection (Figure 2C). Using confocal ﬂuorescence microscopy,
we conformed that Btk colocalizes with swollen, but not resting,
A fumigatus conidia during phagocytosis (Figure 2D). However,
Ibrutinib had no inhibitory effect on phagocytosis (Figure 2E).
Ibrutinib impaired fungal growth control by macrophages
(Figure 2F). These observations suggest that A fumigatus–
dependent macrophage Btk signaling is endosomally driven and
dependent on TLR9. Btk has also been shown to regulate re-
active oxygen species production, inﬂammasome activation,
chemotaxis, and adhesion in myeloid cells.6-10 Further studies
have shown that BTK and TEC kinase are also important for
myeloid immunity to C albicans.11,12 Furthermore, Ibrutinib is
known to have off-target effects on other TEC kinases.13,14 Future
studies should focus on deﬁning the wider impact of Ibrutinib on
TEC kinase-dependent innate immunity to fungi.15
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Figure 2. Endosomally driven Btk responses during human macrophage infection with A fumigatus are required for optimal fungal growth control. (A) TLR9 en-
gagement and BTK phosphorylation are required for NFAT activation in response to A fumigatus in hMDMS. hMDMs were pretreated with Ibrutinib (1 mM), the TLR9-blocking
nucleotideODN2088 (10 mM), or ODN nucleotide control (10 mM) for 1 hour. Macrophages were then infected withA fumigatus swollen conidia (MOI5 1) for 1 hour. Whole cell
lysates were separated by SDS-PAGE, followed by western blotting. Membranes were probed with anti-NFATc1 and Histone H3 antibodies. (B-C) BTK mediates an endosomal
NF-ĸB activation pathway in human macrophages. (B) Monocyte-derived macrophages were pretreated with Scramble or BTK-targeting siRNA (100 nM) for 72 hours and
additionally with cytochalasin D (10 mM) or vehicle. Macrophages were stimulated with eGFP A fumigatus swollen conidia (MOI 5 1) for 1 hour, and NFATc1 and NFKB
translocation weremeasured by confocal microscopy. Nuclear translocation was quantiﬁed by calculating the percent overlap of the nuclear DAPI and transcription factor–linked
ﬂuorophore channels. Data were calculated from 7 ﬁelds of view taken at randomper biological repeat. Mean and standard deviation of 3 biological repeats are represented. (C)
Whole cell lysates were separated by SDS-PAGE, followed by western blotting. Membranes were probed with anti-BTK and anti–b-actin antibodies. Statistical analysis was
performed using paired Student t tests: ns, not signiﬁcant; *P, .05; NS, nonstimulated. (D) BTK is recruited to the membranes of endosomes containing swollen but not resting
conidia in hMDMs. Representative confocal microscopy of monocyte-derived macrophages infected with eGFP expressing A fumigatus (green) (MOI 5 1) at 45 minutes
propidium iodide stained for BTK (red) and nuclei (blue) (original magniﬁcation360). (a) Nuclei; (b) BTK; (c) eGFP; (d) composite images. (E) Ibrutinib does not block A fumigatus
phagocytosis. Monocyte-derived macrophages were pretreated with Ibrutinib (1 mM) for 1 hour. Macrophages were infected with biotinylated A fumigatus-GFP (green
ﬂuorescent protein) swollen conidia (MOI 5 1) for 2 hours. External conidia were then counterstained with Cy3 biotin antibody, and phagocytosis was measured by ﬂow
cytometry. (F) Ibrutinib impairs macrophage control of fungal growth in vitro. Monocyte-derived macrophages were pretreated with Ibrutinib (1 mM) for 1 hour. Cells were
stimulated with A fumigatus swollen conidia (MOI 5 1) for 6 hours. Galactomannan levels were measured in the tissue culture supernatants. UT, untreated.
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Footnotes
The online version of this article contains a data supplement.
There is a Blood Commentary on this article in this issue.
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TO THE EDITOR:
Treatment of AL amyloidosis with bendamustine: a study of
122 patients
Paolo Milani,1,2,* Stefan Scho¨nland,3,* Giampaolo Merlini,1,2 Christoph Kimmich,3 Andrea Foli,1,2 Tobias Dittrich,3 Marco Basset,1,2
Carsten Mu¨ller-Tidow,3 Tilmann Bochtler,3 Giovanni Palladini,1,2,† and Ute Hegenbart3,†
1Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Department of Molecular Medicine, University of Pavia,
Pavia, Italy; and 3Department of Internal Medicine V, Hematology/Oncology/Rheumatology, Amyloidosis Center, University of Heidelberg, Heidelberg, Germany
Chemotherapy for light chain (AL) amyloidosis is based on com-
binations developed for multiple myeloma.1 A better under-
standing of susceptibility of the AL underlying clone to speciﬁc
types of treatments2 and the ability to identify cytogenetic
patterns with different clinical outcomes3,4 are beginning to
change the approach to this rare and still fatal disease. De-
spite the high response rates to ﬁrst-line regimens, treatment
of relapsed/refractory patients remains an important unmet
need.5 Relapsed patients may have a good outcome if treated
before organ progression.6,7 Light chain amyloidosis caused by
immunoglobulin M–producing clones (IgM-AL amyloidosis) is
a distinct clinical entity and poses additional problems in
the design of the therapeutic strategy.8 Rituximab- and
bortezomib-based regimens developed for Waldenstro¨m
macroglobulinemia9 have been evaluated in IgM-AL amyloid-
osis and are considered ﬁrst-line options for these patients,9,10
and bendamustine is being evaluated in a phase 2 trial in re-
lapsed AL amyloidosis.11
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